# Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

> **NCT01029730** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 55 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Bortezomib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01029730
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2014-10
- **Final completion:** 2016-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2016-08-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01029730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01029730, "Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01029730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*